AIRMID CRITICAL CARE PRODUCTS, INC. — Department of Defense SBIR Phase I: X224-OCSO1
AIRMID CRITICAL CARE PRODUCTS, INC. — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $74,299. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code X224-OCSO1 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $74,299
- Agency
- Department of Defense · Air Force
- Program / Phase
- SBIR · Phase I
- Topic
- X224-OCSO1
- Solicitation
- X22.4
- NAICS
- —
- Place of performance
- DC
- Period
- 2022-11-02 → 2023-02-04
Description
As learned from the COVID pandemic, treating lung inflammation requires extensive, intensive care resources and has a very high mortality. Yet, even before COVID, it was recognized that artificial ventilators are often set beyond natural lung capacity, directly causing lung injuries, while manual bag-type ventilators have no breath size control, resulting in inadvertent over-inflation. Unfortunately, no data is currently available to track damage being done by inadvertent overinflation. This affects patients being treated by USAF personnel during peacetime and when treating traumatic injuries. Patients with traumatic brain injury (TBI) are particularly at risk, as over-inflation directly reduces blood flow to the injured brain, increasing death or, for survivors, post-injury disability. To address these unmet dangers, AirMid is developing a Data-Integrated Convertible Ventilator Circuit (DiCVC) that is compatible with AirMid’s Volume-Controlled Manual Ventilator (VCMV) and mechanical ventilators. This system will add the necessary elements to ensure patients receive Lung-Protective Ventilation (LPV), thereby ensuring breaths are tailored to safe limits specific to each patient. This, therefore, represents a new uncompromising standard of care that will provide first-ever protection from inadvertent harm that currently continues to drive high ICU resource use that translates into tens of billions in cost.